CRISPR-Cas-amplified urinary biomarkers for multiplexed and portable cancer diagnostics
Source abstract
Abstract
Abstract Synthetic biomarkers, bioengineered sensors that generate molecular reporters in diseased microenvironments, represent an emerging paradigm in precision diagnostics. Despite the utility of DNA barcodes as a multiplexing tool, their susceptibility to nucleases in vivo has limited their utility. Here we exploit chemically stabilized nucleic acids to multiplex synthetic biomarkers and produce diagnostic signals in biofluids that can be ‘read out’ via CRISPR nucleases. The strategy relies on microenvironmental endopeptidase to trigger the release of nucleic acid barcodes and polymerase-amplification-free, CRISPR-Cas-mediated barcode detection in unprocessed urine. Our data suggest that DNA-encoded nanosensors can non-invasively detect and differentiate disease states in transplanted and autochthonous murine cancer models. We also demonstrate that CRISPR-Cas amplification can be harnessed to convert the readout to a point-of-care paper diagnostic tool. Finally, we employ a microfluidic platform for densely multiplexed, CRISPR-mediated DNA barcode readout that can potentially evaluate complex human diseases rapidly and guide therapeutic decisions.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: CRISPR and Genetic Engineering · Single-cell and spatial transcriptomics · Cancer Genomics and Diagnostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (53)
Show source-provided references
1. Gardner, L., Kostarelos, K., Mallick, P., Dive, C. & Hadjidemetriou, M. Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome. Nat. Rev. Clin. Oncol. 19, 551–561 (2022).10.1038/s41571-022-00645-x ↗
2. Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71–88 (2019).10.1038/s41576-018-0071-5 ↗
3. Kwong, G. A. et al. Synthetic biomarkers: a twenty-first century path to early cancer detection. Nat. Rev. Cancer 21, 655–668 (2021).10.1038/s41568-021-00389-3 ↗
4. Kwong, G. A. et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat. Biotechnol. 31, 63–70 (2013).10.1038/nbt.2464 ↗
5. Ronald, J. A., Chuang, H. Y., Dragulescu-Andrasi, A., Horia, S. S. & Gambhira, S. S. Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker. Proc. Natl Acad. Sci. USA 112, 3068–3073 (2015).10.1073/pnas.1414156112 ↗
6. Hori, S. S. & Gambhir, S. S. Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci. Transl. Med. 3, 109ra116 (2011).
7. Aalipour, A. et al. Engineered immune cells as highly sensitive cancer diagnostics. Nat. Biotechnol. 37, 531–539 (2019).10.1038/s41587-019-0064-8 ↗
8. Mannocci, L. et al. High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries. Proc. Natl Acad. Sci. USA 105, 17670–17675 (2008).10.1073/pnas.0805130105 ↗
9. Burgess, D. J. Spatial transcriptomics coming of age. Nat. Rev. Genet. 20, 317 (2019).10.1038/s41576-019-0129-z ↗
10. Ullal, A. V. et al. Cancer cell profiling by barcoding allows multiplexed protein analysis in fine needle aspirates. Sci. Transl. Med. 6, 219ra9 (2014).10.1126/scitranslmed.3007361 ↗
11. Dahlman, J. E. et al. Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics. Proc. Natl Acad. Sci. USA 114, 2060–2065 (2017).10.1073/pnas.1620874114 ↗
12. Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385–389 (2019).10.1038/s41586-019-1272-6 ↗
13. Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Correspondence, J. S. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164, 57–68 (2016).10.1016/j.cell.2015.11.050 ↗
14. Chabon, J. J. et al. Integrating genomic features for non-invasive early lung cancer detection. Nature 580, 245–251 (2020).10.1038/s41586-020-2140-0 ↗
15. Sun, K. et al. Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Res. 29, 418–427 (2019).10.1101/gr.242719.118 ↗
16. Larson, M. H. et al. A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection. Nat. Commun. 12, 1–11 (2021).10.1038/s41467-020-20314-w ↗
17. Edvard Smith, C. I. & Zain, R. Therapeutic oligonucleotides: state of the art. Annu. Rev. Pharmacol. Toxicol. 59, 605–630 (2019).10.1146/annurev-pharmtox-010818-021050 ↗
18. Tabrizi, S. J. et al. Targeting huntingtin expression in patients with Huntington’s disease. N. Engl. J. Med. 380, 2307–2316 (2019).10.1056/NEJMoa1900907 ↗
19. Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238–248 (2017).10.1038/nbt.3765 ↗
20. Chen, J. S. et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science 360, 436–439 (2018).10.1126/science.aar6245 ↗
21. Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423–1437 (2013).10.1038/nm.3394 ↗
22. Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).10.1158/2159-8290.CD-21-1059 ↗
23. Du, B. et al. Tailoring kidney transport of organic dyes with low-molecular-weight PEGylation. Bioconjug. Chem. 31, 241–247 (2020).10.1021/acs.bioconjchem.9b00707 ↗
24. Kwong, G. A. et al. Mathematical framework for activity-based cancer biomarkers. Proc. Natl Acad. Sci. USA 112, 12627–12632 (2015).10.1073/pnas.1506925112 ↗
25. Choi, C. H. J., Zuckerman, J. E., Webster, P. & Davis, M. E. Targeting kidney mesangium by nanoparticles of defined size. Proc. Natl Acad. Sci. USA 108, 6656–6661 (2011).10.1073/pnas.1103573108 ↗
26. Gootenberg, J. S. et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science 356, 438–442 (2017).10.1126/science.aam9321 ↗
27. Gootenberg, J. S. et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a and Csm6. Science 360, 439–444 (2018).10.1126/science.aaq0179 ↗
28. Myhrvold, C. et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science 360, 444 (2018).10.1126/science.aas8836 ↗
29. Harrington, L. B. et al. Programmed DNA destruction by miniature CRISPR-Cas14 enzymes. Science 362, 839–842 (2018).10.1126/science.aav4294 ↗
30. Kaminski, M. M., Abudayyeh, O. O., Gootenberg, J. S., Zhang, F. & Collins, J. J. CRISPR-based diagnostics. Nat. Biomed. Eng. 5, 643–656 (2021).10.1038/s41551-021-00760-7 ↗
31. Stein, C. A. & Castanotto, D. FDA-approved oligonucleotide therapies in 2017. Mol. Ther. 25, 1069–1075 (2017).10.1016/j.ymthe.2017.03.023 ↗
32. Shen, W. et al. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat. Biotechnol. 37, 640–650 (2019). 2019 376.10.1038/s41587-019-0106-2 ↗
33. Kim, J. et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N. Engl. J. Med. 381, 1644–1652 (2019).10.1056/NEJMoa1813279 ↗
34. Paunovska, K., Loughrey, D. & Dahlman, J. E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet. 23, 265–280 (2022).10.1038/s41576-021-00439-4 ↗
35. Dudani, J. S., Ibrahim, M., Kirkpatrick, J., Warren, A. D. & Bhatia, S. N. Classification of prostate cancer using a protease activity nanosensor library. Proc. Natl Acad. Sci. USA 115, 8954–8959 (2018).10.1073/pnas.1805337115 ↗
36. Morrison, C. Nanobody approval gives domain antibodies a boost. Nat. Rev. Drug Discov. 18, 485–487 (2019).10.1038/d41573-019-00104-w ↗
37. Massa, S. et al. Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging. Bioconjug. Chem. 25, 979–988 (2014).10.1021/bc500111t ↗
38. Fridy, P. C. et al. A robust pipeline for rapid production of versatile nanobody repertoires. Nat. Methods 11, 1253–1260 (2014).10.1038/nmeth.3170 ↗
39. Danino, T. et al. Programmable probiotics for detection of cancer in urine. Sci. Transl. Med. 7, 289ra84 (2015).10.1126/scitranslmed.aaa3519 ↗
40. Naba, A. et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell. Proteom. 11, M111.014647 (2012).10.1074/mcp.M111.014647 ↗
41. Hynes, R. O. & Naba, A. Overview of the matrisome—an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 4, a004903 (2012).10.1101/cshperspect.a004903 ↗
42. Kirkpatrick, J. D. et al. Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Sci. Transl. Med. 12, 262 (2020).10.1126/scitranslmed.aaw0262 ↗
43. DuPage, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064–1072 (2009).10.1038/nprot.2009.95 ↗
44. Welch, N. L. et al. Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants. Nat. Med. 28, 1083–1094 (2022).10.1038/s41591-022-01734-1 ↗
45. Devoogdt, N. et al. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc. Natl Acad. Sci. USA 100, 5778 (2003).10.1073/pnas.1037154100 ↗
46. Devoogdt, N., Revets, H., Ghassabeh, G. H. & De Baetselier, P. Secretory leukocyte protease inhibitor in cancer development. Ann. NY Acad. Sci. 1028, 380–389 (2004).10.1196/annals.1322.044 ↗
47. Pawar, N. R., Buzza, M. S. & Antalis, T. M. Membrane-anchored serine proteases and protease-activated receptor-2 (PAR-2)-mediated signaling: co-conspirators in cancer progression. Cancer Res. 79, 301 (2019).10.1158/0008-5472.CAN-18-1745 ↗
48. Fayard, B. et al. The serine protease inhibitor protease nexin-1 controls mammary cancer metastasis through LRP-1-mediated MMP-9 expression. Cancer Res. 69, 5690–5698 (2009).10.1158/0008-5472.CAN-08-4573 ↗
49. Kwon, E. J., Dudani, J. S. & Bhatia, S. N. Ultrasensitive tumour-penetrating nanosensors of protease activity. Nat. Biomed. Eng. 1, 54 (2017).10.1038/s41551-017-0054 ↗
50. Kaminski, M. M. et al. A CRISPR-based assay for the detection of opportunistic infections post-transplantation and for the monitoring of transplant rejection. Nat. Biomed. Eng. 4, 601–609 (2020).10.1038/s41551-020-0546-5 ↗
51. Tauriello, D. V. F. et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538–543 (2018).10.1038/nature25492 ↗
52. Chakladar, S. et al. A mechanism-based inactivator of glycoside hydrolases involving formation of a transient non-classical carbocation. Nat. Commun. 5, 1–8 (2014).10.1038/ncomms6590 ↗
53. Ballard, Z. S. et al. Deep learning-enabled point-of-care sensing using multiplexed paper-based sensors. npj Digit. Med. 3, 1–8 (2020).10.1038/s41746-020-0274-y ↗